Immune Modifiers

Published on 08/02/2015 by admin

Filed under Basic Science

Last modified 08/02/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1782 times

Chapter 17 Immune Modifiers

Systemic Steroids

MOA (Mechanism of Action)

Side Effects

Important Notes

Introduction to Monoclonal Antibodies

Monoclonal antibodies (mAbs) belong to a broad category of agents (often called simply biologics) with a very large number of effects and clinical indications. The common denominator among all these drugs is the use of engineered proteins that are antibodies. There are two main categories of biologic drugs: mAbs and dimeric fusion proteins.

mAbs are produced by the body’s immune system (by B lymphocytes) for the function of recognizing, binding, and subsequently destroying infectious agents that display foreign antigens. By creating antibodies that target antigens that are part of a disease process, the disease process can potentially be inhibited or completely destroyed.

To produce large quantities of an antibody, an animal first needs to be exposed to an antigen so that the B cells are able to produce the specific antibody. Second, a method of collecting the antibody-producing cell and enabling it to produce massive quantities is required. This is accomplished by fusing two cells together into a hybridoma. Antibody-producing cells (which have a limited life span) are then fused with cells that have an unlimited life span (a cancer cell, specifically a B-lymphoma cancer cell called a myeloma), which creates cells that can indefinitely produce antibodies. In a batch of these cells, there are many different cells, giving rise to many different clones of future generations (polyclonal). The isolation and growth of single cells that produce the desired antibody results in a monoclonal production of antibodies. These monoclonal hybridomas can be grown in cultures or in mice.

Newer technologies are enabling the animal (usually mouse) portion of the antibody to be less and less, so that the resulting antibody is mostly human and therefore not destroyed by the patient’s own immune system for being a foreign antibody by human antimurine antibodies (HAMAs). Chimeric (human-mouse combination) antibodies contain fewer mouse regions than full mouse antibodies. Humanization involves replacing most of the mouse antibody with equivalent human regions while keeping only the variable, antigen-specific regions intact. Humanized mAbs have more human regions than chimeric mAbs do. Finally, fully human mAbs that contain no mouse regions are now being created (Figure 17-1).

Fusion Proteins

Fusion proteins are antibodies but are engineered differently than mAbs. The antigen portion is fused to the Fc fragment. The dimeric molecule can then bind to the specific cell surface binding protein and allow the activity of the Fc portion of the antibody to be directed to the cell. For example, etanercept is a combination of tumor necrosis factor (TNF) receptor bound to the antibody Fc fragment. The drug binds TNF, and the Fc fragment results in inactivation and removal of circulating TNF.

Use of Monoclonal Antibodies

The list of uses for mAbs is growing, but the major categories are as follows:

Conjugating or combining other molecules can provide special functions to the mAb. For example, attaching radioactive isotopes can deliver radiation to provide highly localized radiation to kill tumor cells. An example is ibritumomab, which is a CD20 mAb bound to radioactive yttrium. Conjugating toxins is another approach to delivering highly targeted cytotoxicity. An example is gemtuzumab ozogamicin; the antibody-bound toxin calicheamicin dimethyl hydrazide is cleaved from the antibody inside the cell and binds to DNA, producing apoptosis.

Notes

Clinical uses for each mAb are changing and thus are not specifically listed for each drug. For drugs with which there is considerable clinical experience, separate sections will discuss further details.

Table 17-2 will not be fully inclusive by the time it is published because of the rapid growth of this area of medicine. Some drugs listed may not yet be approved for use.

Table 17-2 Monoclonal Antibodies

Name Type Target
Rituximab Chimeric CD20 on B lymphocytes
Ocrelizumab Humanized CD20 on B lymphocytes
Ofatumumab Human CD20 on B lymphocytes
Tositumomab Mouse

Ibritumomab Mouse

Epratuzumab Humanized CD22 on B lymphocytes Alemtuzumab Humanized CD52 on B and T lymphocytes Muromonab Mouse CD3 on T lymphocytes Efalizumab Humanized CD11a on T lymphocytes Inolimomab Mouse CD25 (IL-2) on T lymphocytes Basiliximab Chimeric CD25 (IL-2) on T lymphocytes Daclizumab Humanized CD25 (IL-2) on T lymphocytes Gemtuzumab Humanized CD33 on hematopoietic cells Bevacizumab Humanized Vascular-endothelial growth factor (VEGF) Ranibizumab Humanized Vascular-endothelial growth factor (VEGF) Cetuximab Chimeric Epidermal growth factor receptor (EGFR) Satumomab Mouse Tumor-associated glycoprotein TAG-72 Capromab Mouse PSA (prostate), bound to 111In Omalizumab Humanized IgE (increased in asthma) Eculizumab Humanized C5 (complement) Palivizumab Humanized Fusion protein of RSV Trastuzumab Humanized HER2 (EGF) Infliximab Chimeric TNF-α Adalimumab Human TNF-α Certolizumab pegol Humanized TNF-α, bound to polyethylene glycol Denosumab Human Receptor activator for nuclear factor κ B ligand (RANKL) in bone

EGF, epidermal growth factor; HER2, human epidermal growth factor receptor 2; 131I, iodine-131; IgE, immunoglobulin E; IL, interleukin; 111In, indium-111; PSA, prostate-specific antigen; TNF, tumor necrosis factor; 90Y, yttrium-90.

B-Cell Biologics

MOA (Mechanism of Action)